In vitro: Baicalein suppresses mitogen induced T cell proliferation and cytokine secretion in vitro. Pre-treatment with baicalein significantly suppresses Con A or anti-CD3/CD28 mAb induced proliferation as well as cytokine secretion at 25 μM. Baicalein treatment induces DNA binding of NF-κB but inhibits thioredoxin activity in the nuclear compartment. Baicalein suppresses proliferation, migration, and invasion of MDA-MB-231 cells in a time- and dose-dependent manner. Baicalein significantly decreases the expression of SATB1 in MDA-MB-231 cells. Baicalein also downregulates the expression of Wnt1 and β-catenin proteins and transcription level of Wnt/β-catenin-targeted genes. In vivo: Baicalein suppresses induction of graft versus host disease but does not inhibit homeostatic proliferation of T-cells in mice. This observation clearly shows potent anti-inflammatory activity of baicalein in vivo. Rats treated with baicalein are protected against an increase in heart to body weight ratio, plasma level of brain natriuretic peptides, intraventricular septum thickness, myocardial collagen volume of left ventricle (all P<0.05, respectively). The antifibrotic effects of baicalein are further illustrated by the suppressed expression of left ventricle pro-collagens I and III accompanied by the decreased expression of 12-lipoxygenase, and by reduced expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases. Baicalein can inhibit cardiac fibrosis in hypertensive rats.
Phytomedicine. 2024 Feb 16.
Baicalein improves the symptoms of polycystic ovary syndrome by mitigating oxidative stress and ferroptosis in the ovary and gravid placenta
Baicalein purchased from AbMole
Trop J Pharm Res. 2020 Nov;Vol. 19 No. 7.
Baicalein inhibits cell development in papillary thyroid cancer by regulating miR-206/RAP1B pathway
Baicalein purchased from AbMole
 |
Source | Tropical Journal of Pharmaceutical Research 2020 Nov. Figure 1. baicalein (Abmole Bioscience Inc, Houston, TX, USA) |
| Method | Cell culture and treatment | |
| Cell Lines | The human PTC cell line TPC-1 | |
| Concentrations | 10, 20, 50, or 100 μM | |
| Incubation Time | 72 h | |
| Results | The Transwell assay showed that the number of migrating or invading cells in the 50 μM baicalein group was less than that in the 0 μM baicalein group |
| Cell Experiment | |
|---|---|
| Cell lines | MDA-MB-231 cells |
| Preparation method | MDA-MB-231 cells are routinely digested, collected, and then seeded in 96-well plates at a density of 8×10^3 cells/well. After incubation for 12-24 hours, cells are treated with 0, 20, 40, 60, 80, 100, and 120 μM baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours |
| Concentrations | 0, 20, 40, 60, 80, 100, and 120 μM |
| Incubation time | 12-24 h |
| Animal Experiment | |
|---|---|
| Animal models | Female (age 6–8 weeks) athymic nude mice |
| Formulation | dissolved in 10% DMSO and 90% sesame oil to form an emulsion |
| Dosages | 25 mg/kg |
| Administration | i.p. |
| Molecular Weight | 270.24 |
| Formula | C15H10O5 |
| CAS Number | 491-67-8 |
| Solubility (25°C) | 54 mg/mL in DMSO |
| Storage | 2-8°C, protect from light |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Products |
|---|
| Izeltabart
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models. |
| Cofetuzumab
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
| Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
| M3554 (anti-GD2 ADC)
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity. |
| OGT2115
OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
